Novateor Research Laboratories (BSE: NOVATEOR.BO) Stock Competitors & Peer Comparison
See NOVATEOR.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NOVATEOR.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NOVATEOR.BO | ₹35.10 | +9.69% | 212.4M | 206.47 | ₹0.17 | N/A |
| LENSKART.NS | ₹707.20 | +4.01% | 1.2T | 243.83 | ₹2.90 | N/A |
| LENSKART.BO | ₹706.60 | +3.94% | 1.2T | 243.62 | ₹2.90 | N/A |
| MOLBIO.NS | ₹1,288.30 | +0.23% | 161.4B | 111.26 | ₹11.58 | N/A |
| MOLBIO.BO | ₹1,288.60 | +0.28% | 148.5B | 111.29 | ₹11.58 | N/A |
| VOEPL.BO | ₹507.35 | +3.40% | 16.2B | 101.67 | ₹4.99 | N/A |
| HSIL.BO | ₹415.00 | -2.24% | 5.9B | 27.78 | ₹14.94 | N/A |
| YASHOPTICS.NS | ₹133.90 | +1.44% | 3.3B | 41.07 | ₹3.26 | N/A |
| RAAJMEDI.BO | ₹102.49 | -0.24% | 1.4B | 119.17 | ₹0.86 | N/A |
| CHOKSI.BO | ₹228.70 | -0.54% | 1.3B | -326.71 | -₹0.70 | N/A |
Stock Comparison
Lenskart Solutions Limited (NSE: LENSKART.NS)
NOVATEOR.BO vs LENSKART.NS Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, LENSKART.NS has a market cap of 1.2T. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while LENSKART.NS trades at ₹707.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas LENSKART.NS's P/E ratio is 243.83. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to LENSKART.NS's ROE of N/A. Regarding short-term risk, NOVATEOR.BO is less volatile compared to LENSKART.NS. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check LENSKART.NS's competition here
Lenskart Solutions Limited (BSE: LENSKART.BO)
NOVATEOR.BO vs LENSKART.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, LENSKART.BO has a market cap of 1.2T. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while LENSKART.BO trades at ₹706.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas LENSKART.BO's P/E ratio is 243.62. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to LENSKART.BO's ROE of +0.09%. Regarding short-term risk, NOVATEOR.BO is less volatile compared to LENSKART.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check LENSKART.BO's competition here
Molbio Diagnostics Limited (NSE: MOLBIO.NS)
NOVATEOR.BO vs MOLBIO.NS Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, MOLBIO.NS has a market cap of 161.4B. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while MOLBIO.NS trades at ₹1,288.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas MOLBIO.NS's P/E ratio is 111.26. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to MOLBIO.NS's ROE of N/A. Regarding short-term risk, NOVATEOR.BO is less volatile compared to MOLBIO.NS. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check MOLBIO.NS's competition here
Molbio Diagnostics Limited (BSE: MOLBIO.BO)
NOVATEOR.BO vs MOLBIO.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, MOLBIO.BO has a market cap of 148.5B. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while MOLBIO.BO trades at ₹1,288.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas MOLBIO.BO's P/E ratio is 111.29. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to MOLBIO.BO's ROE of N/A. Regarding short-term risk, NOVATEOR.BO is less volatile compared to MOLBIO.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check MOLBIO.BO's competition here
Virtuoso Optoelectronics Limit (BSE: VOEPL.BO)
NOVATEOR.BO vs VOEPL.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, VOEPL.BO has a market cap of 16.2B. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while VOEPL.BO trades at ₹507.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas VOEPL.BO's P/E ratio is 101.67. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to VOEPL.BO's ROE of +0.05%. Regarding short-term risk, NOVATEOR.BO is less volatile compared to VOEPL.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check VOEPL.BO's competition here
Hemant Surgical Industries Ltd. (BSE: HSIL.BO)
NOVATEOR.BO vs HSIL.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, HSIL.BO has a market cap of 5.9B. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while HSIL.BO trades at ₹415.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas HSIL.BO's P/E ratio is 27.78. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to HSIL.BO's ROE of +0.14%. Regarding short-term risk, NOVATEOR.BO is less volatile compared to HSIL.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check HSIL.BO's competition here
Yash Optics & Lens Ltd. (NSE: YASHOPTICS.NS)
NOVATEOR.BO vs YASHOPTICS.NS Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, YASHOPTICS.NS has a market cap of 3.3B. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while YASHOPTICS.NS trades at ₹133.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas YASHOPTICS.NS's P/E ratio is 41.07. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to YASHOPTICS.NS's ROE of N/A. Regarding short-term risk, NOVATEOR.BO is less volatile compared to YASHOPTICS.NS. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check YASHOPTICS.NS's competition here
Raaj Medisafe India Limited (BSE: RAAJMEDI.BO)
NOVATEOR.BO vs RAAJMEDI.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, RAAJMEDI.BO has a market cap of 1.4B. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while RAAJMEDI.BO trades at ₹102.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas RAAJMEDI.BO's P/E ratio is 119.17. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to RAAJMEDI.BO's ROE of +0.06%. Regarding short-term risk, NOVATEOR.BO is less volatile compared to RAAJMEDI.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check RAAJMEDI.BO's competition here
Choksi Asia Limited (BSE: CHOKSI.BO)
NOVATEOR.BO vs CHOKSI.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, CHOKSI.BO has a market cap of 1.3B. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while CHOKSI.BO trades at ₹228.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas CHOKSI.BO's P/E ratio is -326.71. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to CHOKSI.BO's ROE of +0.13%. Regarding short-term risk, NOVATEOR.BO is less volatile compared to CHOKSI.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check CHOKSI.BO's competition here
Shree Pacetronix Limited (BSE: SHREEPAC.BO)
NOVATEOR.BO vs SHREEPAC.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, SHREEPAC.BO has a market cap of 597.7M. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while SHREEPAC.BO trades at ₹159.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas SHREEPAC.BO's P/E ratio is 144.91. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to SHREEPAC.BO's ROE of +0.19%. Regarding short-term risk, NOVATEOR.BO is less volatile compared to SHREEPAC.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check SHREEPAC.BO's competition here
Mohini Health & Hygiene Ltd. (NSE: MHHL.NS)
NOVATEOR.BO vs MHHL.NS Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, MHHL.NS has a market cap of 558M. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while MHHL.NS trades at ₹30.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas MHHL.NS's P/E ratio is 9.53. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to MHHL.NS's ROE of N/A. Regarding short-term risk, NOVATEOR.BO is similarly volatile compared to MHHL.NS. This indicates similar risk in terms of short-term price fluctuations for NOVATEOR.BO.Check MHHL.NS's competition here
KMS Medisurgi Limited (BSE: KMSMEDI.BO)
NOVATEOR.BO vs KMSMEDI.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, KMSMEDI.BO has a market cap of 438.2M. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while KMSMEDI.BO trades at ₹132.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas KMSMEDI.BO's P/E ratio is 179.46. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to KMSMEDI.BO's ROE of +0.03%. Regarding short-term risk, NOVATEOR.BO is similarly volatile compared to KMSMEDI.BO. This indicates similar risk in terms of short-term price fluctuations for NOVATEOR.BO.Check KMSMEDI.BO's competition here
GKB Ophthalmics Limited (BSE: GKB.BO)
NOVATEOR.BO vs GKB.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, GKB.BO has a market cap of 315M. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while GKB.BO trades at ₹62.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas GKB.BO's P/E ratio is -10.19. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to GKB.BO's ROE of +0.06%. Regarding short-term risk, NOVATEOR.BO is similarly volatile compared to GKB.BO. This indicates similar risk in terms of short-term price fluctuations for NOVATEOR.BO.Check GKB.BO's competition here
Kretto Syscon Limited (BSE: KRETTOSYS.BO)
NOVATEOR.BO vs KRETTOSYS.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, KRETTOSYS.BO has a market cap of 270.9M. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while KRETTOSYS.BO trades at ₹0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas KRETTOSYS.BO's P/E ratio is 222.22. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to KRETTOSYS.BO's ROE of +0.00%. Regarding short-term risk, NOVATEOR.BO is less volatile compared to KRETTOSYS.BO. This indicates lower risk in terms of short-term price fluctuations for NOVATEOR.BO.Check KRETTOSYS.BO's competition here
Span Divergent Limited (BSE: SDL.BO)
NOVATEOR.BO vs SDL.BO Comparison September 2026
Novateor Research Laboratories (BSE: NOVATEOR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVATEOR.BO stands at 212.4M. In comparison, SDL.BO has a market cap of 201.3M. Regarding current trading prices, NOVATEOR.BO is priced at ₹35.10 on the BSE, while SDL.BO trades at ₹27.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVATEOR.BO currently has a P/E ratio of 206.47, whereas SDL.BO's P/E ratio is 125.43. In terms of profitability, NOVATEOR.BO's ROE is N/A, compared to SDL.BO's ROE of +2.01%. Regarding short-term risk, NOVATEOR.BO is similarly volatile compared to SDL.BO. This indicates similar risk in terms of short-term price fluctuations for NOVATEOR.BO.Check SDL.BO's competition here